Oct 15
Too much of a good thing? A flood of data is slowing clinical trials.
10/15/2025
In an industry driven by scientific curiosity and innovation, the notion that too much data could be a drawback is almost blasphemy. But with a single phase 3 trial now generating nearly six million data points, it may be time to pare down protocols, according to a new study.
Read the full article by PharmaVoice here.
Related Blog Posts
Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites
To kick off 2026, we spoke with industry experts and leaders in the Clinical Research News community about what they expect and look forward to in the new year. More than ever before, artificial intelligence took center stage. Read the full article featuring Allison Cuff Shimooka from Clinical Research News here.
Trendspotting: Artificial Intelligence, Impact of Global Policies, Data Harmonization
To kick off 2026, we spoke with industry experts and leaders in the Bio-IT World community about what they expect and look forward to in the new year. Read the full article featuring Allison Cuff Shimooka from Bio-It World here.
More 2026 Clinical Predictions
This is part 2 of my article about predictions for the clinical trials industry in 2026. From my reporting on AI growing pains, site-network shakeups, and the never-ending sponsor–site tension over feasibility and budgets, it’s clear the industry is carrying plenty of unresolved business into the new year. Read the full article featuring Rob DiCicco…